Integrum Bilan de santé

Santé financière contrôle des critères 6/6

Integrum possède un total de capitaux propres de SEK179.8M et une dette totale de SEK0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont SEK199.8M et de SEK20.0M.

Informations clés

Ratio d'endettement

SEK 0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	SEK 46.18m
Fonds propres	SEK 179.78m
Total du passif	SEK 19.97m
Total des actifs	SEK 199.75m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 6Y1 ( SEK110.6M ) dépassent ses passifs à court terme ( SEK15.5M ).

Passif à long terme: Les actifs à court terme de 6Y1 ( SEK110.6M ) dépassent ses passifs à long terme ( SEK4.4M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 6Y1 est sans dette.

Réduire la dette: 6Y1 n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 5.5%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 6Y1 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 6Y1 dispose d'une marge de trésorerie suffisante pour 2.2 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 10.1 % chaque année.

Integrum Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

New minor risk - Shareholder dilution

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

New major risk - Share price stability

Full year 2023 earnings released

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q1, 2023 Results on Sep 02, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

Art Clinic, Center of Excellence in the Nordic countries, has treated its first patient with Integrum's OPRA™ Implant System

Third quarter 2021 earnings released

BG Klinik Tübingen to Treat Thumb Amputees with Integrum's OPRA Implant System

Integrum AB Collaboration with Onkos Pave the Way for Further Growth in the US

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines